Cysteine Metabolism Controls T Cell Function and Cancer Immunity

This groundbreaking study reveals how immune cells strategically allocate the amino acid cysteine to support different cellular functions, with profound implications for cancer immunotherapy. The research addresses a fundamental question in immunology: how do T cells decide how to use the nutrients they acquire?

Researchers at Johns Hopkins studied CD8+ T cells, the immune system's primary cancer-fighting cells. They discovered that these cells use cysteine through two competing pathways: one produces glutathione (GSH) for antioxidant protection, while the other provides sulfur for iron-sulfur cluster synthesis essential for cell proliferation.

The key finding was that when NFS1, the enzyme responsible for iron-sulfur cluster production, was deleted from activated T cells, the cells became exhausted and lost their anti-cancer effectiveness. Conversely, when researchers blocked cysteine from entering the glutathione pathway or enhanced iron-sulfur metabolism, tumor control improved significantly.

This metabolic competition was validated in human hepatocellular carcinoma samples, where disrupted iron-sulfur metabolism correlated with T cell exhaustion. The findings suggest that therapeutic interventions could redirect cysteine usage to optimize immune function while maintaining beneficial effects.

The research opens new avenues for cancer immunotherapy by targeting metabolic pathways rather than just immune checkpoints. By understanding how nutrients are partitioned within immune cells, clinicians may develop more effective treatments that enhance the body's natural cancer-fighting abilities.